{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-24-000032","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.167026+00:00","generated_at":"2026-06-01T23:06:45.304726+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Elicio Therapeutics reports Q1 2024 net loss of $11.8M; provides clinical updates for ELI-002","bullets":["Net loss $11.8M ($1.15 per share) vs $8.0M in Q1 2023; R&D expense increased to $7.6M from $5.5M.","Cash and equivalents $11.9M as of March 31, 2024, down from $12.9M at December 31, 2023.","ELI-002 2P Phase 1 data published in Nature Medicine; ELI-002 7P Phase 1 preliminary data at ASCO in June 2024.","Randomized Phase 2 trial of ELI-002 7P enrollment expected to complete in Q4 2024; interim analysis in Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-24-000032","json":"https://secwatch.observer/filing/0001601485-24-000032.json","markdown":"https://secwatch.observer/filing/0001601485-24-000032.md","text":"https://secwatch.observer/filing/0001601485-24-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000032/0001601485-24-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000032/angn-20240515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:06:45.304726+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb54de0cee17f69f589f95ea43716cbf7a34e53b","claim":"Elicio Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income $11.8 million, EPS $1.15.","evidence_excerpt":"Net loss for the first quarter of 2024 was $11.8 million, compared to $8.0 million for the first quarter of 2023. Net loss per share for the first quarter of 2024 was $1.15 compared to $24.77 for the first quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000032/0001601485-24-000032-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"$11.8 million"},{"label":"EPS","value":"$1.15"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}